Newsroom

PRINCETON, New Jersey, TOKYO e ZURIGO--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. e Araris Biotech AG ("Araris") oggi hanno annunciato il completamento del periodo di revisione relativo a un nuovo farmaco sperimentale (IND) da parte della U.S. Food and Drug Administration (FDA) su ARC-02, un anticorpo farmaco-coniugato (ADC) in corso di sviluppo per il trattamento dei linfomi non Hodgkin. Taiho Oncology può così dare inizio a uno studio clinico di fase 1 su ARC-02 con...

PRINCETON, Nueva Jersey; TOKIO; y ZÚRICH--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. y Araris Biotech AG (“Araris”) anunciaron hoy que la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) ha completado el período de revisión de un nuevo fármaco en investigación (IND) para ARC-02, un conjugado de anticuerpo y fármaco (ADC) en desarrollo para el tratamiento del linfoma no Hodgkin, lo que permite a Taiho Oncology iniciar un ensayo clínico de fase 1 con e...

PRINCETON, N.J. & TOKYO & ZÜRICH--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. en Araris Biotech AG ('Araris') hebben vandaag bekendgemaakt dat de Amerikaanse Food and Drug Administration (FDA) de beoordelingsperiode voor het Investigational New Drug (IND)-programma voor ARC-02, een antilichaam-geneesmiddelconjugaat (ADC) dat wordt ontwikkeld voor de behandeling van non-Hodgkin-lymfoom, heeft afgerond. Hiermee kan Taiho Oncology een Fase 1-dosisverhogingsstudie voor ARC...

PRINCETON, New Jersey & TOKIO & ZÜRICH--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., und Araris Biotech AG („Araris“) gaben heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) die Prüfungsphase für den Antrag auf Zulassung eines neuen Prüfpräparats (Investigational New Drug, IND) für ARC-02 abgeschlossen hat, ein Antikörper-Wirkstoff-Konjugat (ADC), das zur Behandlung von Non-Hodgkin-Lymphomen entwickelt wird. Damit kann Taih...

PRINCETON, New Jersey et TOKYO et ZURICH--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. et Araris Biotech AG (« Araris ») annoncent aujourd’hui que la Food and Drug Administration (FDA) des États-Unis a achevé la période d’examen de sa demande IND pour l'ARC-02, un conjugué anticorps-médicament (CAM) en développement pour le traitement du lymphome non hodgkinien, permettant à Taiho Oncology de lancer un essai clinique d’escalade de dose de phase 1 évaluant l'ARC-02. Taih...

CHATHAM, N.J.--(BUSINESS WIRE)--Bowker has announced a new partnership with Narrative Muse that will give its customers across the publishing ecosystem access to content discovery and audience intelligence services. Through the partnership, Bowker customers will be able to access Narrative Muse’s audience analysis and discovery services, helping authors and publishers better understand audience connection before release. “Authors and publishers are always looking for thoughtful ways to strength...

PHOENIX & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Forrester (Nasdaq: FORR) today launched the Forrester AI (formerly Izola) agent for Microsoft 365 Copilot, enabling clients to securely access trusted Forrester research and guidance directly within their daily workflows at no additional cost for existing license holders. This announcement follows Forrester’s recent Microsoft Teams integration, continuing to redefine how clients engage with research and advisory firms. In today’s fast‑moving, AI‑powe...

NEW YORK--(BUSINESS WIRE)--HOK has acquired ROSSETTI, a Detroit-based architecture firm recognized nationally for its sports venue design and renovation work. The merger strengthens HOK’s position as one of the world’s leading sports, recreation and entertainment design practices. The combined firm will operate as HOK + ROSSETTI during the integration. ROSSETTI’s team, led by Matt Rossetti, FAIA, LEED AP, will continue to operate from Detroit—a market where HOK has long sought a physical presen...

BALTIMORE--(BUSINESS WIRE)--The Board of Directors of Constellation Energy Corporation (Nasdaq: CEG) declared a quarterly dividend of $0.4265 per share on Constellation’s common stock. The dividend is payable on June 5, 2026, to shareholders of record as of 5 p.m. Eastern time on May 15, 2026. About Constellation Constellation Energy Corporation (Nasdaq: CEG), a Fortune 200 company headquartered in Baltimore, is the largest private-sector power producer in the world and the nation's largest pro...

IRVINE, Calif.--(BUSINESS WIRE)--Nihon Kohden, a global leader in neurodiagnostic, patient, monitoring and ventilation, today announced it is expanding the reach of NomadAir® with Connect — its established at-home sleep apnea diagnostic system — into dental sleep medicine. The company will feature the solution at the American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, taking place May 1–3 in Chicago (Booth 408). The expansion comes as growing collaboration between dentists and sle...